Tempus AI Draws Mixed Analyst Views as Cantor Fitzgerald Sets $80 Target on Platform Potential

AI-Driven Precision Medicine Company Faces Analyst Scrutiny

Tempus AI Inc (NASDAQ:TEM) found itself at the center of Wall Street debate this week as three major firms issued divergent assessments of the diagnostics and data company's growth trajectory1

1

2

2

. Cantor Fitzgerald initiated coverage with an Overweight rating and $80 price target, arguing the market fundamentally misunderstands Tempus AI's Data & Applications business by treating it as a life sciences vendor rather than recognizing platform-level economics1

1

. Analyst Sarah James drew parallels to DDOG and SNOW, noting Tempus AI sells data and AI tools to 19 of the 20 largest pharmaceutical companies and more than 250 biotechs across their R&D pipelines1

1

. This positioning allows the AI in healthcare company to benefit from overall biopharma activity rather than depending on any single drug or trial.

Revenue Growth Catalysts Point to $2.4 Billion by 2028

Cantor Fitzgerald identified five underappreciated catalysts that could drive Tempus AI stock revenue above $2.4 billion by 2028, up from $1.3 billion in 20251

1

. The firm projects comprehensive genomic profiling volumes could nearly double as physician adoption expands beyond the current 40-50% penetration rate1

1

. Migration to xT CDx and xF reimbursement could lift AI-driven treatment selection tests pricing more than 40%, from approximately $1,850 to over $2,6001

1

. Minimal residual disease monitoring represents a roughly $20 billion opportunity, with volumes already climbing 38% quarter over quarter in Q21

1

. Management estimates algorithmic diagnostics could create 50-100x their cost in value, representing another potential upside the market may be underappreciating1

1

.

Personalis Acquisition Reshapes Growth Outlook

Piper Sandler upgraded Tempus AI to Overweight from Neutral with a $76 price target, citing three newly visible growth drivers3

3

. The pending Personalis acquisition gives Tempus AI ownership of a differentiated tumor-informed MRD platform, which had already accounted for most of its minimal residual disease sales2

2

3

3

. The positive INTerpath-001 readout increases the strategic value of this Personalis acquisition and positions Tempus AI as the tumor sequencing provider for a potentially new therapeutic class3

3

. FDA approval of tumor-only xT CDx clears a critical hurdle for unified ADLT pricing for xT, with the xF product potentially following in the second half of 20273

3

.

Cautious View Highlights Treatment Selection Concentration

Rothschild Redburn initiated coverage at Neutral with a $67 price target, taking a more measured stance on the AI-enabled precision medicine company2

2

. The firm noted that while Tempus AI's Data & Applications business is differentiated, it lacks visibility on long-term growth, with the business mainly focused on treatment selection2

2

. Rothschild Redburn forecast a 20% 2026-29 revenue CAGR, the slowest of three companies it covers in the precision medicine space2

2

. The firm expects Tempus AI to reach free cash flow breakeven in 2027 with an adjusted EBITDA margin of 11%, rising to 20% in 20302

2

. This matters because profitability timelines directly impact how investors value AI in healthcare companies trading at premium multiples. Watch for quarterly updates on physician adoption rates, xT CDx pricing dynamics, and integration progress with Personalis to gauge whether the platform thesis or vendor characterization proves accurate.